Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $997.03M. The enterprise value is $573.37M.
Market Cap$997.03M
Enterprise Value$573.37M
Share Statistics
Bicara Therapeutics Inc. has 54,781,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,781,950
Owned by Insiders17.57%
Owned by Institutions52.28%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -16.75%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-16.75%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicara Therapeutics Inc. is ―. Bicara Therapeutics Inc.’s PEG ratio is -0.56.
PE Ratio―
PS Ratio0.00
PB Ratio1.93
Price to Fair Value1.93
Price to FCF-12.67
Price to Operating Cash Flow-8.13
PEG Ratio-0.56
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0.00 and earned -68.00M in profits. Earnings per share was -1.25.
Revenue0.00
Gross Profit0.00
Operating Income-82.39M
Pretax Income-67.81M
Net Income-68.00M
EBITDA-82.33M
Earnings Per Share (EPS)-1.25
Cash Flow
In the last 12 months, operating cash flow was -112.98M and capital expenditures -82.00K, giving a free cash flow of -113.06M billion.
Operating Cash Flow-112.98M
Free Cash Flow-113.06M
Free Cash Flow per Share-2.06
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.46
52-Week Price Change-13.91%
50-Day Moving Average16.62
200-Day Moving Average13.04
Relative Strength Index (RSI)57.80
Average Volume (3m)631.51K
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 18, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 27.93, with Debt / Equity ratio of 0.51%
Current Ratio27.93
Quick Ratio27.93
Debt to Market Cap<0.01
Net Debt to EBITDA7.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid 187.00K in taxes.
Income Tax187.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -6.78, with an EV/FCF ratio of -6.14.
EV to Sales0.00
EV to EBITDA-6.78
EV to Free Cash Flow-6.14
EV to Operating Cash Flow-6.14
Balance Sheet
Bicara Therapeutics Inc. has $290.17M in cash and marketable securities with $1.98M in debt, giving a net cash position of $288.19M billion.
Cash & Marketable Securities$290.17M
Total Debt$1.98M
Net Cash$288.19M
Net Cash Per Share$5.26
Tangible Book Value Per Share$9.04
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $33.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.00
Price Target Upside81.32% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―